These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1539 related articles for article (PubMed ID: 16204063)

  • 1. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
    Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
    Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
    van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
    Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
    Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL
    Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
    Tipping AJ; Deininger MW; Goldman JM; Melo JV
    Exp Hematol; 2003 Nov; 31(11):1073-80. PubMed ID: 14585372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
    Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C
    Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
    Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
    Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
    Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
    Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.